Revolution Medicines Inc.
Revolution Medicines Updates on Financial Guidance and Clinical Progress for RMC-6236
Summary
Revolution Medicines, Inc. announced on July 15, 2024, that it expects a net loss for the year ended December 31, 2024, to be between $560 million and $600 million, including estimated non-cash stock-based compensation expense of approximately $70 million to $80 million. The company also provided updates on the clinical safety, tolerability, and activity data for its RAS(ON) multi-selective inhibitor, RMC-6236, in a monotherapy first-in-human study for patients with previously treated pancreatic ductal adenocarcinoma (PDAC). Additionally, the company reported preliminary progression-free survival (PFS) data for patients with metastatic PDAC treated with RMC-6236 in the second-line setting and plans for a global, randomized Phase 3 trial.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement